tbuckley/cabot-search huggingface dataset:
Case 15-1963
Journal: New England Journal of Medicine (1963)

Presentation of Case A thirty-year-old woman was admitted to the hospital because of progressive dyspnea. Three weeks before entry the patient had a febrile exanthem after a similar illness in her children had been diagnosed as varicella. One week later a sore throat developed; a throat culture showed a normal flora. During convalescence, while away on a vacation, she became aware of progressive fatigue, aching of the legs and an increasingly severe cough that occasionally produced mucoid sputum. The sore throat subsided, but the cough persisted and was associated with progressively severe shortness of breath; mild exertion and lying flat . . .
LG-64COMBINATORIAL TARGETING OF ONCOGENIC FGFR1 GENE REARRANGEMENTS IN PEDIATRIC GLIOMAS
Authors: Aesha Vakil, Amanda Silva, Harry J. Han, Namrata Choudhari, Phillip B. Storm, Adam C. Resnick, Monika A. Davare, Angela J. Waanders
Journal: Neuro-Oncology (2016)
SOME PROBLEMS IN MEDICAL ETHICS
Authors: R P GIOVACCHINI, G H BECKER, M J BRUNNER, F E DUNLAP
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
New perspectives in mental health services in Shanghai
Authors: M Zhang, J Ji, H Yan
Journal: American Journal of Psychiatry (1997)

This article reports developments in mental health services in Shanghai during the past several years, including family education and involvement, new forms of community services, psychological consultation programs, hot line services and crisis intervention, dealing with psychological problems in general hospitals, and nursing care for elderly patients with dementia. The authors reevaluate and outline the new perspectives in mental health services in Shanghai.
A comparison of clinicopathological characteristics and survival outcomes between symptomatic and screen detected breast cancer in Japanese women.
Authors: Hitoshi Inari, Satoru Shimizu, Tatsuya Yoshida, Nobuyasu Suganuma, Takashi Yamanaka, Hirotaka Nakayama, Ayumi Yamanaka, Yasushi Rino, Munetaka Masuda
Journal: Journal of Clinical Oncology (2015)

4 Background: In Japan from 2000, mammography screening has been introduced into the breast cancer screening for women aged 50 or above, however in the early 2000s, breast cancer screening involved palpation only and mammography combined. Only a few studies have been reported clinicopathological characteristics and survival outcomes of this screening detected breast cancer in Japan. This study evaluated effectiveness of this screening by comparing symptomatic and screen detected breast cancer Methods: From January 2000 to December 2004, 1159 patients were underwent surgery for treatment of breast cancer at single hospital in Japan. Among them, 977 patients were symptomatic and 182 patients were this screen detected, and follow-up was performed from the date of the diagnosis until the date of death or the end of follow-up, March 2015. We retrospectively reviewed the clinical and pathologic data. Results: Screen detected breast cancer was associated with more breast conservation surgery, smaller tumor size, less lymph node involvement, more hormone receptor positive, more non-invasive carcinoma and less adjuvant chemotherapy compared with symptomatic breast cancer (P &lt; 0.05). In univariate analyses, women with screen-detected tumors had improved overall survival compared to women with tumors that were detected symptomatically (10-year OS: 90.6% vs.80.4%, P = 0.01). According to ages, in women older than 50 years women with screen-detected tumors had improved overall survival compared to women with tumors that were detected symptomatically (10-year OS:87.7%vs.76.7%, P = 0.006). Screen detection of all patients was independently associated with improved overall survival outcomes (HR 0.47, P = 0.002, respectively), screen detection in women older than 50 years was also similar (HR 0.494, P = 0.007, respectively). Conclusions: This study showed that early detection in breast cancer screening had led to increase in breast conservation rate, avoidance of axillary lymph node dissection, more hormone receptor positive, avoidance of adjuvant chemotherapy, and improvement of survival rate.
Reactive astrocytes potentiate tumor aggressiveness in a murine glioma resection and recurrence model
Authors: Onyinyechukwu Okolie, Juli R. Bago, Ralf S. Schmid, David M. Irvin, Ryan E. Bash, C. Ryan Miller, Shawn D. Hingtgen
Journal: Neuro-Oncology (2016)

Surgical resection is a universal component of glioma therapy. Little is known about the postoperative microenvironment due to limited preclinical models. Thus, we sought to develop a glioma resection and recurrence model in syngeneic immune-competent mice to understand how surgical resection influences tumor biology and the local microenvironment. We genetically engineered cells from a murine glioma mouse model to express fluorescent and bioluminescent reporters. Established allografts were resected using image-guided microsurgery. Postoperative tumor recurrence was monitored by serial imaging, and the peritumoral microenvironment was characterized by histopathology and immunohistochemistry. Coculture techniques were used to explore how astrocyte injury influences tumor aggressiveness in vitro. Transcriptome and secretome alterations in injured astrocytes was examined by RNA-seq and Luminex. We found that image-guided resection achieved >90% reduction in tumor volume but failed to prevent both local and distant tumor recurrence. Immunostaining for glial fibrillary acidic protein and nestin showed that resection-induced injury led to temporal and spatial alterations in reactive astrocytes within the peritumoral microenvironment. In vitro, we found that astrocyte injury induced transcriptome and secretome alterations and promoted tumor proliferation, as well as migration. This study demonstrates a unique syngeneic model of glioma resection and recurrence in immune-competent mice. Furthermore, this model provided insights into the pattern of postsurgical tumor recurrence and changes in the peritumoral microenvironment, as well as the impact of injured astrocytes on glioma growth and invasion. A better understanding of the postsurgical tumor microenvironment will allow development of targeted anticancer agents that improve surgery-mediated effects on tumor biology.
Near-Infrared Light Triggered ROS-activated Theranostic Platform based on Ce6-CPT-UCNPs for Simultaneous Fluorescence Imaging and Chemo-Photodynamic Combined Therapy
Authors: Caixia Yue, Chunlei Zhang, Gabriel Alfranca, Yao Yang, Xinquan Jiang, Yuming Yang, Fei Pan, Jesús M. de la Fuente, Daxiang Cui
Journal: Theranostics (2016)

Many drug controlled release methods have been integrated in multifunctional nanoparticles, such as pH-, redox-, temperature-, enzyme-, and light-responsive release.However, few report is associated with the ROS responsive drug controlled release.Herein, a thioketal linker-based ROS responsive drug (camptothecin conjugated with thioketal linker, abbreviated as TL-CPT) was prepared and the thioketal linker could be cleaved by ROS(reactive oxygen species).To achieve cancer simultaneous optical imaging, photodynamic therapy and chemotherapy, the photosensitizer Chlorin e6(Ce6), TL-CPT and carboxyl-mPEG were loaded on the upconversion nanoparticles (UCNPs), which were named as Ce6-CPT-UCNPs.Under 980 nm laser irradiation, Ce6-CPT-UCNPs emitted a narrow emission band at 645-675 nm which was overlapped with Ce6 absorption peak.Ce6 absorbed the light to produce ROS, which was used for photodynamic therapy and to cleave the thioketal linker in Ce6-CPT-UCNPs to release camptothecin for chemotherapy.Meanwhile, Ce6 absorbed the light, was used for near-infrared fluorescence imaging.The in vivo biodistribution studies showed that the prepared nanoparticles had high orthotopic lung cancer targeting efficiency.The in vivo therapeutic results demonstrated that NCI-H460 lung cancers could be completely eliminated by combining chemo-and photodynamic therapy under 980 nm laser irradiation.The prepared multifunctional Ce6-CPT-UCNPs have great potential in applications such as cancer targeted fluorescent imaging, simultaneous ROS activated chemo-and photodynamic therapy in near future.
Differential Effects of Bisphosphonate on Paget’s Disease and Metastatic Prostatic Carcinoma-Bone Scan Findings
Authors: W. F. EDDIE LAU, RODNEY HICKS, DAVID BINNS
Journal: Clinical Nuclear Medicine (2001)

EDDIE LAU, W. F. F.R.A.N.Z.C.R.; HICKS, RODNEY F.R.A.C.P., M.D.; BINNS, DAVID A.N.M.T., DIP.APP. SCI. Author Information
Psycho-social assistence for oncological patients, to reveal and answer to the patient and caregiver's psychological discomfort
Authors: R. Manzo, G. Petrillo, R. Guida, M.L. Lentini Graziano, G. Massaro, G. Pignataro, N. Silvestro, N. Caruso, I. Vitale, F. Laudato, V. Montesarchio
Journal: Annals of Oncology (2015)
Abstract 5094: Effect of Celiprolol on Prevention of Cardiovascular Events in Vascular Ehlers-Danlos Syndrome
Authors: Kim-Thanh Ong, Jérôme Perdu, Henri Plauchu, Julie De Backer, Anne De Paepe, Joseph Emmerich, Xavier Jeunemaitre, Dominique Germain, Patrick Collignon, Gabriella Georgesco, Erwan Bozec, Jean-Sébastien Hulot, Stéphane Laurent, Pierre Boutouyrie
Journal: Circulation (2009)

Background: Vascular Ehlers-Danlos syndrome (vEDS) is a rare severe genetic disease which results from mutations in the gene encoding type III procollagen (COL3A1), characterized by vascular and/or hollow organic ruptures. No treatment is yet validated. We tested the ability of celiprolol, a beta1-adrenoceptor antagonist with a beta2-adrenoceptor agonist action, for preventing the complications of vEDS in a prospective, randomized, open, blinded endpoints trial. Methods: Fifty three previously untreated vEDS patients were randomized to a 5-year treatment with either celiprolol (n=25) or no treatment (n=28). The two groups were matched for demographic, medical historic and clinical characteristics. Celiprolol was up-titrated from 100 to 400 mg by steps of 100 mg every 6 months. The primary end-point was an arterial event (rupture or dissection, fatal or not) occurring during follow-up. Secondary endpoints were intestinal or uterine rupture or major clinical events, related to vEDS, judged by the event committee. Results: Mean duration of follow-up was 47 (±15) months. The study was ended prematurely by the safety monitoring board since significant differences were reached between two groups. The primary endpoint was reached by 5 patients (20%) in the celiprolol group and by 14 patients (50%) in the control group (hazard ratio, 0.36; 95% CI, 0.15 to 0.88; P=0.04). Primary plus secondary endpoints occurred in 6 patients (24%) in the celiprolol group and in 17 patient (61%) in the control group (hazard ratio, 0.31; 95% CI, 0.14 to 0.71; P=0.0097). Conclusions: Celiprolol effectively reduced both vascular complications and organic ruptures in vEDS patients.
LG-40UNUSUAL NON-PILOCYTIC HISTOPATHOLOGICAL FEATURES OF PEDIATRIC INFRATENTORIAL GLIOMAS WITH BRAF FUSION GENE: A REPORT OF 2 CASES
Authors: Christine Haberler, Andreas Kiefer, Barbara Jauk, Christian Dorfer, Thomas Czech, Giles Vince, Manuela Badiali, Irene Slavc
Journal: Neuro-Oncology (2016)

LG-40. UNUSUAL NON-PILOCYTIC HISTOPATHOLOGICAL FEATURES OF PEDIATRIC INFRATENTORIAL GLIOMAS WITH BRAF FUSION GENE: A REPORT OF 2 CASES Christine Haberler1, Andreas Kiefer2, Barbara Jauk2, Christian Dorfer1, Thomas Czech1, Giles Vince2, Manuela Badiali3, and Irene Slavc1; Medical University of Vienna, Vienna, Austria; Academic Hospital of Klagenfurt, Klagenfurt, Austria; Microcitemico Hospital, Cagliari, Italy Genomic profiling studies have unraveled distinct molecular changes in different pediatric glioma entities. High grade gliomas commonly harbor H3F3A mutations or PDGFRA amplifications, diffuse low grade gliomas frequently display mutations in the FGFR1 or MYB1 gene, and pilocytic astrocytomas are characterized by MAPK pathway alterations including BRAF fusions and mutations. We report two infratentorial tumors with unusual morphological features. Patient 1 is a 15-year-old girl with a 6 months history of headache and a 4.5x4.5x6 cm cerebellar cystic tumor with contrast enhancement. A near gross total resection was performed. Histopathologically, the tumor was partly clear-celled but showed focally also some rosettes reminiscent of a RGNT. Vascular proliferations in a nonpilocytic tumor raised the suspicion of a malignant glioma. Patient 2, a 4-year-old girl presented with cephalea/strabism and had a cystic 2,8 x 2,9 x 2,5 cm tumor in the pineal region, radiologically compatible with a pilocytic astrocytoma. A gross total resection was performed. Histopathologically, ependymoma-like features with perivascular pseudorosettes, clear cells and vascular proliferations were present. In both cases immunhistochemical expression pattern confirmed a glioma without H3F3A K27M and BRAF V600E mutation, however classification and grading were difficult. Sequencing revealed in both tumors a KIAA1549– BRAF fusion. As this alteration is predominantly but not exclusively found in pilocytic astrocytomas and histopathologically no clear-cut signs ofmalignancy werepresent, no adjuvant treatment was administered. Both patients show no tumor recurrence/progression 32 and 21 months postoperatively. These cases emphasize the importance of molecular analyses in tumors with unusual morphological feature. Neuro-Oncology 18:iii78–iii96, 2016. doi:10.1093/neuonc/now075.40 #The Author(s) 2016. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Modification of Nuclear Restriction In Vitro by Plasma From Tumor-Bearing Animals 2
Authors: Dorothy E. Schumm, Thomas E. Webb
Journal: JNCI Journal of the National Cancer Institute (1975)

Putative regulatory macromolecules, which may be useful in diagnosis or tumor detection, were identified in the peripheral blood plasma of tumor-bearing animals. We monitored the components by measuring their ability to stimulate messenger RNA (mRNA) release from isolated nuclei in a cell-free system of rat liver nuclei in fortified homologous cytosol. This in vitro test system exhibited near-normal in vivo nuclear RNA restriction. When added to the assay at a protein concentration of 3.0 mg/ml, dialyzed plasma from rats or mice with chemically induced transplantable or primary tumors stimulated mRNA release from 87% to more than 300% over control plasma from normal rats. Plasma from partially hepatectomized rats stimulated only 26% over control plasma. The test system derived from rat liver seemed to permit the monitoring of plasma from other species. Available evidence, particularly relating to tumor-host-interaction, suggests, but does not prove, that regulatory components are released from the tumor cells to the circulation.
MB-41INTRAVENTRICULAR ONCOLYTIC ENGINEERED HERPES SIMPLEX VIRUS PROLONGS SURVIVAL AND REDUCES SPINAL METASTASES IN MICE BEARING HUMAN GROUP 3 MEDULLOBLASTOMA
Authors: Tina Etminan, Eric Ring, Li Nan, Blake Moore, Anita Hjelmeland, Rong Li, G. Yancey Gillespie, Gregory Friedman
Journal: Neuro-Oncology (2016)
Therapeutic activity of a new antibody-drug immunoconjugate, IMMU-110, in preclinical studies targeted against multiple myeloma
Authors: R. Stein, G. L. Griffiths, T. Cardillo, R. Blumenthal, I. D. Horak, D. M. Goldenberg
Journal: Journal of Clinical Oncology (2004)

6535 Background: CD74, a cell-surface-expressed epitope of the HLA class II-associated invariant chain [Ii], is a unique target for antibody-drug immunoconjugate therapy, being a transmembrane chaperone molecule that actively directs transport from the cell surface to an endosomal compartment. IMMU-110 is a drug immunoconjugate comprised of doxorubicin (dox) conjugated to the humanized anti-CD74 monoclonal antibody (MAb), hLL1, at 6–8 drug molecules per IgG molecule. The dox is linked to partially-reduced antibody inter-chain disulfide groups using 4-[N-maleimidomethyl] cyclohexane-1 carboxylhydrazide. We recently reported that IMMU-110 has potent therapeutic effects in a non-Hodgkin's lymphoma-SCID mouse model. Methods: Here we examine the efficacy of IMMU-110 for therapy of multiple myeloma (MM), based on the high prevalence of CD74 expression on MM specimens, using in vitro assays on MM cell lines and in vivo studies in a SCID mouse model of disseminated MM. Results: In vitro cytotoxicity assays demonstrated that in CD74+ cells IMMU-110 yields IC50 values similar to those of free dox, whereas a control MAb-dox conjugate is markedly less toxic. In contrast, activity of IMMU-110 is similar to that of the control conjugate in CD74- cell lines. For example, IMMU-110 was ∼7-fold more potent than the control conjugate on CAG cells. Untreated mice given an i.v. injection of 1x107 MC/CAR cells die of disseminated disease with a median survival time (MST) of 32 days post-injection. A single i.v. protein dose of IMMU-110 of 350 μg, given 5 days after injection of the MC/CAR cells, resulted in extension of MST to >150 days. Unconjugated hLL1 and dox mixed with hLL1 yield MSTs of 61.5 and 68 days, respectively. No significant effects were seen with free dox given at an equivalent dose, or a control conjugate. Similar survival extensions were observed when treatment with IMMU-110 was given 10 days after transplantation of MM cells, and a significant extension of MST was even observed 14 days post-inoculation (from 28 to 35 days P<0.002). Conclusions: IMMU-110 is a drug immunoconjugate showing considerable promise as a new therapeutic for MM. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Immunomedics, Inc. Immunomedics, Inc. Immunomedics Inc.
Chemotherapy of diffuse large-cell lymphoma--rapidly responding patients have more durable remissions.
Authors: J R Anderson, S Ginsberg, A J Gottlieb
Journal: Journal of Clinical Oncology (1986)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1986.4.9.1420 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 3746380 Chemotherapy of diffuse large-cell lymphoma--rapidly responding patients have more durable remissions. J R AndersonxJ R AndersonSearch for articles by this author , S GinsbergxS GinsbergSearch for articles by this author , A J GottliebxA J GottliebSearch for articles by this author https://doi.org/10.1200/JCO.1986.4.9.1420 PDF "Chemotherapy of diffuse large-cell lymphoma--rapidly responding patients have more durable remissions.." Journal of Clinical Oncology, 4(9), pp. 1420–1421© 1986 by American Society of Clinical Oncology
Clinical trial of blood-brain barrier disruption by pulsed ultrasound
Authors: Alexandre Carpentier, Michael Canney, Alexandre Vignot, Vincent Reina, Kevin Beccaria, Catherine Horodyckid, Carine Karachi, Delphine Leclercq, Cyril Lafon, Jean-Yves Chapelon, Laurent Capelle, Philippe Cornu, Marc Sanson, Khê Hoang-Xuan, Jean-Yves Delattre, Ahmed Idbaih
Journal: Science Translational Medicine (2016)

The blood-brain barrier (BBB) limits the delivery of systemically administered drugs to the brain. Methods to circumvent the BBB have been developed, but none are used in standard clinical practice. The lack of adoption of existing methods is due to procedural invasiveness, serious adverse effects, and the complications associated with performing such techniques coincident with repeated drug administration, which is customary in chemotherapeutic protocols. Pulsed ultrasound, a method for disrupting the BBB, was shown to effectively increase drug concentrations and to slow tumor growth in preclinical studies. We now report the interim results of an ultrasound dose-escalating phase 1/2a clinical trial using an implantable ultrasound device system, SonoCloud, before treatment with carboplatin in patients with recurrent glioblastoma (GBM). The BBB of each patient was disrupted monthly using pulsed ultrasound in combination with systemically injected microbubbles. Contrast-enhanced magnetic resonance imaging (MRI) indicated that the BBB was disrupted at acoustic pressure levels up to 1.1 megapascals without detectable adverse effects on radiologic (MRI) or clinical examination. Our preliminary findings indicate that repeated opening of the BBB using our pulsed ultrasound system, in combination with systemic microbubble injection, is safe and well tolerated in patients with recurrent GBM and has the potential to optimize chemotherapy delivery in the brain.